Business Strategies
> Proprietary Pharmaceuticals
Proprietary
pharmaceuticals are often patent-protected or benefit from other
non-patent market exclusivities, which generally allow proprietary
products to maintain their profitability for longer periods of time
than generic products. If a proprietary product has achieved physician
and customer loyalty, it will often remain profitable following the
onset of generic competition, but will usually generate lower profits
than it realized prior to generic competition.
The Company's proprietary pharmaceutical development activities are
focused in three main areas:
•
patent-protected proprietary products in late stages of development;
•
existing chemical compounds in which the development of new forms
(liquid vs. tablets, different dosages or other drug delivery systems
such as our proprietary, novel vaginal ring delivery system) offer
therapeutic or marketing advantages; and
•
new chemical entities in select therapeutic categories, including some
marketed in other countries (but not currently sold in North America).
Barr's proprietary
development activities are focused on expanding its portfolio of female healthcare
products, including additional oral contraceptives and treatments for menopause/perimenopause
and endometriosis. The Company is also pursuing products in urology, developing products
utilizing its innovative transvaginal ring (TVR) drug delivery technology and developing
an oral vaccine product to prevent Adenovirus (types 4 and 7) infections. The Company continues
to identify other proprietary product candidates that further expand its offerings in these areas
while evaluating additional therapeutic categories.
Product Guide 
